Dasatinib in imatinib‐resistant or ‐intolerant chronic‐phase, chronic myeloid leukemia patients: 7‐year follow‐up of study CA180‐034

Dasatinib was approved at 100 mg once daily for imatinib‐resistant or ‐intolerant patients with chronic myeloid leukemia (CML) in chronic phase, based on results of the phase 3 CA180‐034 (NCT00123474) study. Here we present the final 7‐year analysis of this pivotal study, the longest follow‐up to da...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Neil P., Rousselot, Philippe, Schiffer, Charles, Rea, Delphine, Cortes, Jorge E., Milone, Jorge, Mohamed, Hesham, Healey, Diane, Kantarjian, Hagop, Hochhaus, Andreas, Saglio, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094534/
https://www.ncbi.nlm.nih.gov/pubmed/27192969
http://dx.doi.org/10.1002/ajh.24423

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094534/
https://www.ncbi.nlm.nih.gov/pubmed/27192969
http://dx.doi.org/10.1002/ajh.24423

Ejemplares similares